GMP Inspection Preparation Checklist: A Tool for Internal Auditing

This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.

Biological-risk-eval-and-mngmnt-for-md-130x160

Biological Risk Evaluation and Management for Medical Devices

Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.

Editor's Picks

View all

Inova Diagnostics’ Assay Cleared by FDA

Inova’s test can help identify patients who are at severe risk of illness and often need aggressive immunosuppressive therapy.

Indian Drugmaker Draws FDA Warning for Adulterated Products

The firm attributed out-of-specification and out-of-trend assay results for certain tablets to sampling preparation errors but didn’t provide any evidence to support the findings.

Home » VAXGEN RAISES $79M THROUGH SALE OF INTEREST IN OVERSEAS BIOPHARMACEUTICAL MANUFACTURING FACILITY

VAXGEN RAISES $79M THROUGH SALE OF INTEREST IN OVERSEAS BIOPHARMACEUTICAL MANUFACTURING FACILITY

VaxGen, Inc. announced today that it has realized gross proceeds of approximately $79.0 million through the sale of a portion of its common shares in Celltrion, Inc. VaxGen also granted the purchasers an exclusive option to acquire the remainder of its Celltrion shares by December 31, 2006.

Yahoo News (http://biz.yahoo.com/prnews/060629/sfth045.html?.v=61)

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 – Fax (703) 538-7676 – Toll free (888) 838-5578.

Recommended Products

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Biological Risk Evaluation and Management for Medical Devices

Events

Commissioner Gottlieb’s FDA: His First Year and a Look Ahead

Corporate Compliance & Liability: What Medical Product Professionals Need to Know

Clinical Trials in the Precision Medicine Era: New Techniques, New Complexity

What CDER Can and Can’t Do: An Inside Look from an Agency Official

Mastering EU Medical Device Regulation

Top Tips for Establishing Device Supplier Quality Metrics: Develop a World-Class Program to Boost…

Editor's Picks

Inova Diagnostics’ Assay Cleared by FDA

Indian Drugmaker Draws FDA Warning for Adulterated Products

VAXGEN RAISES $79M THROUGH SALE OF INTEREST IN OVERSEAS BIOPHARMACEUTICAL MANUFACTURING FACILITY

Related Products

The Biopharmaceutical Facility of the Future - Webinar CD/Transcript

Aging Aseptic and Biological Manufacturing Facilities - Webinar CD/Transcript

Raw Materials Risk Management in GMP Facilities - Webinar CD/Transcript

Related Events

Emerging Biopharmaceutical Therapies: New Regulations, New Guidelines, New Incentives…

Clinical Trials in the Precision Medicine Era: New Techniques, New Complexity